Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 17

Typewriter Therapeutics Launches With $56 Million Series A

Sep 3, 2026
Typewriter Therapeutics has emerged from stealth with $56 million in Series A financing to develop genetic medicines for cancer, autoimmune diseases, and severe genetic disorders.…
Read More...

World ADC Awards 2026 Shortlist Announced, Recognizing Excellence Across the ADC Industry

Sep 1, 2026
The World ADC Awards 2026 shortlist has been announced, recognizing the organizations, teams, technologies, and individuals driving innovation and advancing the field of antibody-drug…
Read More...

Cipla Licenses HER2 Cancer Drug TQB2102 Across Emerging Markets

Sep 1, 2026
Cipla Limited and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have entered into an exclusive licensing and supply agreement for TQB2102, an…
Read More...

FDA Approves BESREMi for Essential Thrombocythemia After 30 Years

Sep 1, 2026
The U.S. Food and Drug Administration (FDA) has approved PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making…
Read More...

Teva Discusses Lower Medicaid Drug Prices With Trump Administration

Sep 1, 2026
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced a shared commitment with the Trump Administration to explore ways to lower the cost of…
Read More...

Kazia Therapeutics Raises $40 Million to Advance Paxalisib Trials

Sep 1, 2026
Kazia Therapeutics Limited has closed an oversubscribed public offering that generated approximately $40 million in upfront gross proceeds, providing additional funding for the clinical…
Read More...

SK Biopharmaceuticals to In-License Opakalim for Epilepsy Treatment

Aug 31, 2026
SK Biopharmaceuticals has agreed to in-license opakalim, an investigational anti-seizure medicine from Biohaven, in a deal that could reach $795 million and could help the South Korean…
Read More...

FDA Accepts Kowa’s K-911 Glaucoma Drug Application for Review

Aug 31, 2026
The U.S. Food and Drug Administration (FDA) has accepted Kowa Pharmaceuticals America’s New Drug Application (NDA) for K-911, an investigational eye drop being developed to reduce…
Read More...

AusperBio Raises $120 Million to Advance Hepatitis B Drug

Aug 31, 2026
AusperBio Therapeutics has raised $120 million in a Series C financing round to support the development of its experimental treatments for chronic hepatitis B (CHB) and prepare its lead…
Read More...

FDA Approves LISRAYA for Adults With Dermatomyositis

Aug 31, 2026
The U.S. Food and Drug Administration (FDA) has approved Priovant Therapeutics’ LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM), a rare autoimmune…
Read More...
Previous 1 … 15 16 17 18 19 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.